Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
A study from Columbia cancer researchers suggests drugs targeting the SMARCAL1 protein could strike a double blow against many cancers and make immunotherapy even more effective.
A working group of international experts, including Columbia's Mary Beth Terry, evaluated the current evidence around limiting or stopping alcohol use and lowering the risk of certain types of cancer.
A clinical trial based on discoveries made by researchers in Columbia’s Pancreas Center is showing promising results and is now expanding to include more patients.
A new study is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development of new treatments.
Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.
A new mouse model may be critical for understanding the most aggressive types of pancreatic cancer and finding ways to prevent its growth and recurrence.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
Columbia bioengineers are the first to program bacteria that guide immune cells to tumors, which could make more cancers treatable with immunotherapies.